Observational Study of Dapagliflozin for Adults with Type 2 Diabetes and Hypertension Evaluating Its Safety and Effectiveness

What this Trial Is About

Researchers are evaluating the effectiveness and safety of dapagliflozin in people who have type 2 diabetes along with high blood pressure. This observational study focuses on how well dapagliflozin helps control blood sugar and blood pressure in this patient population. The study is sponsored by Boryung Pharmaceutical Co., Ltd and involves monitoring patients over a set period to assess these health outcomes. Participants in this study are those prescribed dapagliflozin under the brand names Trudapa Tab. or Trudapa M SR Tab. as part of their treatment plan. As an observational study, patients receive their usual care and dapagliflozin as prescribed by their doctors, without additional experimental interventions. The study tracks patients from the time they start dapagliflozin and observes their health over at least 12 weeks. During the study, researchers will gather data on blood pressure control and blood sugar levels 12 weeks after starting dapagliflozin. Participants will be asked to cooperate fully and continue in the study to its completion. The study also monitors safety and any side effects that may arise. The total participation lasts at least 12 weeks, with assessments focused on how well the treatments control diabetes and hypertension.

A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension